In a press release on Tuesday, Mar. 26, Moderna announced that it is now working on creating more vaccines for different diseases. In the report, they shared about three new additional vaccines currently being tested in trials. This development is seen as a major advancement in Moderna's strategy following the COVID-19 pandemic.

Fortunately, the trials for these vaccines showed promising results, and with that, Moderna is now moving them into the final stage of testing. This suggests that these vaccines have a good chance of becoming available in the market soon. 

Diversifying the biotech company's vaccine portfolio is a major move because fewer people need Covid-19 vaccines worldwide.

READ NEXT: US CDC Issues New COVID-19 Guidelines, Ending 5-Day Isolation Period for Americans Who Test Positive

Moderna's New Vaccines Aside from Covid-19

At Moderna's fifth annual "Vaccines Day" investor event in Boston, CNBC reported that the company talked about its plans for the future beyond Covid-19. CEO Stéphane Bancel stated that Moderna is dedicated to tackling medical challenges that haven't been fully addressed, especially those related to dormant viruses that can cause health problems later on.

The three vaccines in focus include a candidate targeting norovirus, a common stomach bug causing vomiting and diarrhea, as well as vaccines against Epstein-Barr virus, associated with mono and certain cancers, and a virus causing shingles and chickenpox.

In addition to these advancements, Moderna revealed updates on its broader vaccine pipeline, including combinations to address COVID-19 and influenza, as well as developments in addressing respiratory syncytial virus (RSV) and cytomegalovirus (CMV).

Partnering with Blackstone Life Sciences, Moderna has already secured funding to advance its flu shot program.

Using its mRNA technology, which has proven successful in its COVID-19 vaccine, Moderna aims to revolutionize preventive medicine and become a key player in addressing infectious diseases worldwide.

READ MORE: Pfizer Agrees to Pay $93 Million to Settle Lipitor Cholesterol Drug Antitrust Lawsuit